Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - risankizumabum - lnjektionslösung in einer fertigspritze - lösung: risankizumabum 75.0 mg, sorbitolum 34 mg, dinatrii succinas hexahydricus corresp. natrium 0.149 mg, natrium 0.149 mg, acidum succinicum, polysorbatum 20, aqua ad iniectabile ad solutionem pro 0.83 ml. tela cum: alcohol isopropylicus. - plaque-psoriasis bei erwachsenen, psoriasis-arthritis - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - risankizumabum - lnjektionslösung in einer fertigspritze - risankizumabum 150 mg, natrii acetas trihydricus corresp. natrium 0.209 mg, acidum aceticum glaciale, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - plaque-psoriasis bei erwachsenen, psoriasis-arthritis - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

abbvie ag - risankizumabum - solution injectable en stylo prérempli - risankizumabum 150 mg, natrii acetas trihydricus corresp. natrium 0.209 mg, acidum aceticum glaciale, trehalosum dihydricum, polysorbatum 20, aqua ad iniectabile ad solutionem pro 1 ml. - plaque-psoriasis bei erwachsenen; psoriasis-arthritis - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - bimekizumabum - solution injectable en seringue préremplie - bimekizumabum 160 mg, glycinum, natrii acetas trihydricus, acidum aceticum glaciale, polysorbatum 80, aqua ad iniectabile, ad solutionem pro 1.0 ml corresp., natrium 0.45 mg. - psoriasis en plaques chez l'adulte - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

ucb-pharma sa - bimekizumabum - solution injectable en stylo prérempli - bimekizumabum 160 mg, glycinum, natrii acetas trihydricus, acidum aceticum glaciale, polysorbatum 80, aqua ad iniectabile, ad solutionem pro 1.0 ml corresp., natrium 0.45 mg. - psoriasis en plaques chez l'adulte - biotechnologika

Canada - français - Health Canada

janssen inc - guselkumab - solution - 100mg - guselkumab 100mg - misc. skin and mucous membrane agents

Canada - français - Health Canada

janssen inc - guselkumab - solution - 100mg - guselkumab 100mg - misc. skin and mucous membrane agents

Union européenne - français - EMA (European Medicines Agency)

janssen-cilag international nv - guselkumab - psoriasis - immunosuppresseurs - plaque psoriasis tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritis tremfya, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (dmard) therapy (see section 5.

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - guselkumabum - solution injectable dans une seringue préremplie - guselkumabum 100 mg, saccharum, histidinum, histidini hydrochloridum monohydricum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - plaque psoriasis, psoriasis-arthritis - biotechnologika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

janssen-cilag ag - guselkumabum - solution injectable en stylo prérempli - guselkumabum 100 mg, saccharum, histidinum, histidini hydrochloridum monohydricum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 1 ml. - plaque psoriasis, psoriasis-arthritis - biotechnologika